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Abstract Previous observations indicate that a zinc and phorbol
ester binding factor is necessary for endosome fusion. To further
characterize the role of this factor in the process, we used an in
vitro endosome fusion assay supplemented with recombinant
Rab5 proteins. Both zinc depletion and addition of calphostin C,
an inhibitor of protein kinase C, inhibited endosome fusion in the
presence of active Rab5. Addition of the phorbol ester PMA
(phorbol 12-myristate 13-acetate) reversed the inhibition of
endosome fusion caused by a Rab5 negative mutant. Moreover,
PMA stimulated fusion in the presence of Rab5 immunodepleted
cytosol. These results suggest that the phorbol ester binding
protein is acting downstream of Rab5 in endosome fusion.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
Rab5 is a limiting regulator of early endosome fusion, a
critical step along the endocytotic pathway that immediately
follows the internalization step at the plasma membrane [1,2].
In BHK-21 cells, overexpression of Rab5 wild type
(Rab5:WT) leads to increased early endosome fusion and ele-
vated endocytosis whereas overexpression of a dominant neg-
ative Rab5 mutant (Rab5:S34N) results in decreased early
endosome fusion and reduced endocytosis [1,3,4].
Interestingly, the GTPase de¢cient mutant (Rab5:Q79L)
increases endosome fusion [4,5], suggesting that GTP hydrol-
ysis is not required for the process. In this context, it has been
proposed that Rab5 in its GTP-bound form recruits rabaptin-
5 to the membrane. Rabaptin-5 binding is thought to retard
GTP hydrolysis by blocking the activation of the GTPase
activity of Rab5 by Rab5-GAPs. Thus, the docking/fusion
machinery could remain bound to Rab5 allowing the fusion
to occur [6]. The exact mechanism by which Rab5 produces
all its remarkable e¡ects on endosome fusion is still poorly
understood. A connection between Rab5, Ras and phospha-
tidyl inositol 3-kinase (PI 3-kinase) has been suggested [7^9].
By using a cell-free assay, we have shown that N,N,NP,NP-
tetrakis-(2-pyridylmethyl)ethylenediamine (TPEN), a good
chelator for many metal ions except Ca2 and Mg2, strongly
inhibited endosome fusion. This inhibition could be reversed
by addition of Zn2 but not by other bivalent cations, indi-
cating that the TPEN e¡ect was speci¢c for Zn2 and that a
zinc binding factor is necessary for endosome fusion [10]. We
have also shown that the zinc binding factor is regulated by
phorbol esters [11]. Some of the best characterized zinc and
phorbol ester binding proteins belong to the PKC family [12].
The Cys-rich region of PKC, which coordinates zinc, binds
the natural activator diacylglycerol as well as phorbol esters
[13]. The same region also irreversibly binds the inhibitor
calphostin C (CPC) [14]. When assessed in the in vitro assay,
phorbol 12-myristate 13-acetate (PMA) stimulates endosome
fusion whereas CPC inhibits the process in a zinc dependent
fashion. Moreover, we have shown that a protein containing a
PKC-like cysteine-rich domain is associated to endosomes in a
zinc dependent manner and that the Cys2 region of PKCQ
inhibits endosome fusion probably competing with the phor-
bol ester binding factor for a target molecule [11]. These re-
sults indicate that endosome fusion requires a protein with a
cysteine-rich region similar to the Cys2 region of PKCQ. How-
ever, the function of the phorbol ester binding factor in endo-
some fusion is still unknown.
The aim of this work is to study the functional relationship
between the phorbol ester binding factor and Rab5, probably
the best characterized factor speci¢cally involved in early en-
dosome dynamics. According to the results, the factor is re-
quired for the stimulatory e¡ect in endosome fusion of the
constitutively active mutant Rab5:Q79L. Moreover, activa-
tion of the factor with phorbol ester can overcome the inhib-
itory e¡ect in endosome fusion of the dominant negative mu-
tant Rab5:S34N. Taken together, the results indicate that the
phorbol ester binding factor is required downstream of Rab5
in endosome fusion.
2. Materials and methods
2.1. Materials
J774 E-clone (mannose receptor positive), a macrophage cell line,
was grown to con£uence in minimum essential medium containing
Earle’s salts and supplemented with 10% fetal calf serum. Cytosol
from J774 was the high speed supernatant of a cell homogenate ob-
tained as described [15]. Cytosols were stored at 380‡C and aliquots
(200 Wl) were gel ¢ltered through 1 ml Sephadex G-25 before use in
the fusion assay. Rab5 immunodepleted cytosol was prepared by in-
cubating cytosol overnight at 4‡C with protein A-Sepharose-CL4B
coupled to anti-Rab5 IgG monoclonal. Recombinant Rab5 wild
type and mutants were prepared, puri¢ed, and prenylated as described
[2]. TPEN was obtained from Molecular Probes, Portland, OR, USA.
All other reagents were purchased from Sigma, St. Louis, MO, USA.
FEBS 21326 30-12-98
0014-5793/98/$19.00 ß 1998 Federation of European Biochemical Societies. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 9 8 ) 0 1 5 7 9 - 8
*Corresponding author. Fax: (54) (61) 494117.
E-mail: lmayorga@fmed2.uncu.edu.ar or lmayorga2@hotmail.com
Abbreviations: BSA, bovine serum albumin; CPC, calphostin C;
DAG, diacylglycerol; PA, phorbol 13-monoacetate; PMA, phorbol
12-myristate 13-acetate; GST-Rab5 proteins, glutathione S-transferase
fusion proteins; TPEN, N,N,NP,NP-tetrakis-(2-pyridylmethyl)ethylene-
diamine
FEBS 21326 FEBS Letters 441 (1998) 373^378
2.2. In vitro endosome fusion assay
Early endosomes were prepared by loading J774 E-clone macro-
phages with aggregated monoclonal anti-dinitrophenol (DNP) mouse
IgG (via the Fc receptor) or with DNP-L-glucuronidase (via the mac-
rophage mannose receptor) as previously described [15]. To obtain
endosome enriched fractions, postnuclear fractions were diluted 15-
fold in homogenization bu¡er and centrifuged sequentially at
35 000Ug for 1 min and at 50 000Ug for 5 min. The second pellet
was used for fusion reactions. Fusion between two populations of
endosomes containing either the antibody or the enzyme was per-
formed as previously described [15,16]. The fusion bu¡er (250 mM
sucrose, 0.5 mM EGTA, 20 mM HEPES-KOH pH 7.0, 1 mM dithio-
threitol, 1.5 mM MgCl2, 50 mM KCl, 1 mM ATP, 8 mM creatine
phosphate, 31 U/ml creatine phosphokinase, and 0.25 mg/ml DNP-
BSA) was supplemented with gel ¢ltered cytosol, Rab5 immunode-
pleted cytosol, CPC, ZnCl2, PMA, phorbol 13-monoacetate (PA), N-
ethylmaleimide (NEM), or GST-Rab proteins, as required. The sam-
ples were incubated at 37‡C for 45 min and the reaction was stopped
by cooling on ice.
3. Results
3.1. TPEN and CPC inhibit the Rab5 stimulated endosome
fusion
To address whether the stimulation of endosome fusion
promoted by Rab5 requires the zinc and phorbol ester binding
factor previously described [10,11], we examined the e¡ect of
the zinc chelator TPEN and CPC, a membrane permeant in-
hibitor of several PKC isoforms, in the in vitro endosome
fusion assay. CPC inhibits PKC by irreversibly oxidizing the
phorbol ester binding site, which coordinates zinc, in a light
dependent manner [17].
The in vitro assay does not require addition of exogenous
Rab5, which is present on the membranes and cytosol in-
cluded in the fusion reaction. However, if endosomes are pre-
incubated with 60 mM EDTA for 10 min at 25‡C and washed
by sedimentation prior to the assay, fusion becomes fully de-
pendent on exogenously added activated Rab5 (Rab5+GTPQS
or Rab5:Q79L) (Fig. 1AFig. 2A). Activated Rab5 can sup-
port fusion at very low concentrations of cytosol. We have
used this approach to show that Rab5 dependent fusion is
inhibited by TPEN and CPC. Fig. 1A shows that fusion
among EDTA washed endosomes cannot occur even in the
presence of the non-hydrolyzable GTP analog GTPQS, indi-
cating that the amount of endogenous cytosolic Rab5 in-
cluded in this set of experiments is not enough to support
fusion. When recombinant Rab5:WT and GTPQS are added
together, fusion proceeds. However, if TPEN or CPC is also
added, fusion is blocked. TPEN is a good chelator for many
metal ions, except Ca2 and Mg2. Fig. 1B shows that addi-
tion of Zn2 reverses the e¡ect of TPEN, but only in the
presence of recombinant Rab5:WT and GTPQS. Addition of
Zn2 in the absence of Rab5:WT and GTPQS produced only a
minor recovery of endosome fusion, ruling out the possibility
that the ion could trigger a Rab5 independent fusion process.
GTPQS could activate several GTPases besides Rab5.
Therefore, to assess the requirement of the factor under con-
ditions where only Rab5 was active, we studied the e¡ect of
CPC on endosome fusion in the presence of Rab5:Q79L, a
GTPase defective mutant of Rab5. It has been shown that
Rab5:Q79L stimulates in vitro endosome fusion to the same
extent as Rab5:WT in the presence of GTPQS [5]. Fig. 2A
shows that Rab5:Q79L stimulates fusion among EDTA
washed endosomes and that CPC addition inhibits fusion
but only when zinc and CPC are added together. The zinc
requirement for CPC inhibition of endosome fusion has been
previously described [11].
Similar results were obtained with unwashed endosomes
and saturating concentrations of cytosol. Under these condi-
tions, fusion occurs without the addition of recombinant
Rab5. However, addition of Rab5:Q79L produced a signi¢-
cant enhancement in endosome fusion. CPC inhibited both
the basal and the Rab5 stimulated endosome fusion (Fig.
2B) but only in the presence of zinc. These data suggest
that a zinc dependent factor sensitive to CPC is required for
endosome fusion. Moreover, since Rab5 in the presence of
GTPQS and the constitutively activated Rab5:Q79L putatively
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Fig. 1. Inhibition of Rab5 stimulated endosome fusion by TPEN and CPC. Postnuclear supernatants were incubated with 60 mM EDTA for
10 min at 25‡C. The fractions were then diluted in homogenization bu¡er and endosome enriched fractions were obtained as described in Sec-
tion 2. A: Endosome fusion was assessed at low cytosolic concentrations (0.1 mg/ml) and tested in the following conditions: in the presence or
absence of 40 WM GTPQS, 200 nM Rab5:WT, 3 mM TPEN and 0.5 WM CPC plus 0.3 mM ZnCl2 as described [11]. Fusion was expressed as
a percentage of the value observed in the presence of 40 WM GTPQS plus 200 nM Rab5. B: Endosome fusion was assessed at low cytosolic
concentrations (0.1 mg/ml) and tested in fusion bu¡er containing 3 mM of TPEN and increasing concentrations of ZnCl2 in the presence (b)
or absence (F) of 70 WM GTPQS plus 200 nM Rab5:WT. Fusion was expressed as a percentage of the maximum value observed. The results
shown are representative of at least three experiments.
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bypass the activation steps, the inhibition of endosome fusion
obtained indicates that the zinc binding protein is required
after the activation of Rab5 or in addition to Rab5 activation
(Figs. 1 and 2).
3.2. Phorbol ester reverses the inhibitory e¡ect of Rab5:S34N
on in vitro endosome fusion
The results obtained with TPEN and CPC suggest that the
zinc binding factor is required for the stimulatory e¡ect of
Rab5 on endosome fusion. Two models could account for
these observations: (i) a sequential model where the factor
is part of the pathway activated by Rab5, or (ii) a parallel
model where the zinc binding factor is required in addition to
Rab5 activation for endosome fusion to occur. To distinguish
between these two possibilities, we took advantage of a dom-
inant negative mutant of Rab5 (Rab5:S34N). If the factor
were in a parallel pathway, its activation, via the addition
of phorbol esters, would not overcome the inhibition of in
vitro endosome fusion by Rab5:S34N.
Early endosome and cytosol preparations were incubated
with 300 nM Rab5:S34N and/or 100 nM PMA. As shown
in Fig. 3A, PMA produced a stimulatory e¡ect on endosome
fusion under control conditions [11]. Incubation with
Rab5:S34N strongly inhibited fusion. Interestingly, the inhi-
bition by Rab5:S34N was completely reversed by PMA (Fig.
3A). This observation is consistent with a role of the phorbol
ester binding protein downstream of Rab5.
To con¢rm the observations obtained using Rab5:S34N,
the e¡ect of PMA was assessed in the presence of a Rab5
immunodepleted cytosol. Rab5 immunodepletion substan-
tially inhibited endosome fusion (Fig. 3B). Similar to the e¡ect
observed with Rab5:S34N, the inhibition obtained using
Rab5 immunodepleted cytosol was reversed by PMA. A less
active analog PA was inactive, indicating that the stimulatory
e¡ect of PMA is due neither to the lipidic nature of the com-
pound nor to the solvent (Fig. 3B).
The observations that phorbol ester can promote fusion
with Rab5 immunodepleted cytosol or in the presence of
Rab5:S34N are consistent with a sequential model, i.e. the
PMA binding protein is acting downstream of Rab5.
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Table 1
Requirements of endosome fusion in the presence of PMA
Experimental conditions Percentage of endosome fusion S.D.







PMA+Ro 31-8220 127 10
PMA+NEM 16 5
Endosome fusion (1 mg of cytosolic protein/ml) was tested in the following conditions: PMA, 100 nM PMA; 3cytosol, minus cytosolic proteins;
3KCl, minus salt; 3ATP, minus ATP regenerating system (i.e., ATP, creatine phosphate, and creatine phosphokinase); +staurosporine, plus 10
WM staurosporine; +chelerythrine, plus 10 WM chelerythrine; +Ro 31-8220, plus 10 WM Ro 31-8220; +NEM, vesicles and cytosol were incubated
for 15 min at 4‡C with 1 mM NEM before the fusion reaction, and excess NEM was quenched with 2 mM dithiothreitol. Values are expressed as a
percentage of control fusion without any addition. The data represent the means þ S.D. of at least three independent experiments.
Fig. 2. Inhibition of Rab5:Q79L stimulated endosome fusion by CPC. A: Postnuclear supernatants were incubated with 60 mM EDTA for 10
min at 25‡C. The fractions were then diluted in homogenization bu¡er and endosome enriched fractions were obtained as described in Section
2. Endosome fusion was assessed at low cytosolic concentrations (0.1 mg/ml) and tested in the in the presence or absence of 300 nM
Rab5:Q79L, 0.5 WM CPC, and 0.3 mM ZnCl2. Values are expressed as a percentage of maximum value observed. The data are representative
of at least four independent experiments. B: Fusion among endosomes that were not treated with EDTA was assessed in the presence of 0.7
mg of cytosolic protein/ml and in the presence or absence of 300 nM Rab5:Q79L, 0.5 WM CPC, and 0.3 mM ZnCl2. Values are expressed as a
percentage of control fusion without any addition. The data are representative of at least four independent experiments.
A. Aballay et al./FEBS Letters 441 (1998) 373^378 375
3.3. Characterization of the PMA dependent endosome fusion
The fact that a less active phorbol ester analog was inactive
in the fusion assay suggests that the PMA e¡ect on fusion is
speci¢c. However, to rule out the possibility of a non-speci¢c
e¡ect on fusion, endosome fusion in the presence of PMA was
characterized. Table 1 shows that fusion in the presence of
PMA requires cytosol, KCl, ATP and that it is NEM sensi-
tive. These results indicate that the e¡ect of PMA on endo-
some fusion is speci¢c, requiring all the factors normally as-
sociated with regulated vesicle fusion. Moreover, the PMA
e¡ect was inhibited neither by 10 WM staurosporine or
10 WM chelerythrine, both inhibitors of the catalytic domain
of PKC, nor by the PKC ATP binding site inhibitor Ro 31-
8220, suggesting that a PKC-like kinase activity is not re-
quired.
4. Discussion
Membrane tra⁄cking among intracellular organelles re-
quires the assembly and disassembly of macromolecular com-
plexes that mediate the formation of transport vesicles from
donor compartments, allows for their movement through the
cytoplasm followed by high ¢delity membrane docking, and
fusion with acceptor compartments. Several components of
this machinery have been identi¢ed. However, the process is
still far from being completely characterized. Several well de-
¢ned factors, such as Rab GTPases, are required for transport
but have not yet been precisely con¢gured in the model. Rabs
have been suggested to ensure the directionality of SNAREs
binding [18^21]. Recently, it has been proposed that Rab pro-
teins transiently interact with the t-SNARE allowing the for-
mation of the v/t-SNARE complex by displacement of a neg-
ative regulator [22].
In this study, we have shown that a phorbol ester binding
factor is required for the e¡ect of both wild type Rab5 and the
constitutively activated Rab5 mutant Rab5:Q79L, indicating
that the factor is not necessary for Rab5 activation. In addi-
tion, the fact that activation of the phorbol ester binding
factor by PMA can overcome the inhibitory e¡ect of the
dominant negative mutant Rab5:S34N suggests that the fac-
tor is acting downstream of Rab5. We cannot rule out the
possibility that the inhibitors used (CPC and TPEN) could
inactivate one factor required for Rab5 e¡ects and PMA
could activate another factor that promotes fusion by a
Rab5 independent mechanism. However, we have observed
that fusion between endosomes in the presence of PMA has
several characteristics similar to those described for Rab5 de-
pendent fusion (i.e. it is NEM sensitive and ATP, KCl, and
cytosol dependent). In addition, in a previous report, we have
shown that PMA is inhibitory in the presence of the Cys2
region of PKCQ under conditions that support Rab5 depend-
ent fusion [11]. This observation indicates that conditions that
inhibit PMA regulated fusion also inhibit Rab5 dependent
fusion suggesting that both factors are not acting in independ-
ent pathways.
It has been shown that zinc binding domains are critical
regions that can mediate speci¢c protein-protein interactions
[23]. The phorbol ester binding factor may directly associate
with Rab5. It has already been mentioned that the Rab5
homolog Vps21p interacts with the zinc binding protein
Vps8p [24]. EEA1 is a hydrophilic protein present in cytosol
and early endosome membrane fractions. At its C-terminus,
the protein presents a cysteine-rich motif that is crucial for its
colocalization with the GTPase de¢cient mutant of Rab5 [25].
In addition, it has been proved that EEA1 directly interacts
with both the PI(3)K product phosphatidylinositol 3-phos-
phate and Rab5, linking PI(3)K function to Rab5 regulation
of endosome fusion [9]. Even though this new Rab5 interact-
ing protein binds zinc, it is unlikely that it would interact with
phorbol esters. The known phorbol ester binding domains are
highly similar and it has been shown that point mutations on
the zinc binding domain of PKC completely abolished the
binding of phorbol ester [27]. A sequence alignment between
the zinc and phorbol ester binding domain of rat PKCK and
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Fig. 3. E¡ect of PMA on Rab5:S34N and anti-Rab5 inhibited endosome fusion. A: Endosome fusion was assessed in the presence of 0.7 mg/ml
of cytosolic protein, without further addition (Control), 100 nM PMA (PMA), 300 nM Rab5:S34N (Rab5:S34N), and 100 nM PMA plus
300 nM Rab5:S34N (Rab5:S34N+PMA). Values are expressed as a percentage of control fusion without any addition. The data are represen-
tative of at least four independent experiments. B: Endosome fusion was assessed in the presence of 0.7 mg/ml of control cytosol (Cytosol),
0.7 mg/ml cytosol immunodepleted of Rab5 (CY-Rab5), CY-Rab5 plus 100 nM PMA (CY-Rab5+PMA), and CY-Rab5 plus 100 nM PA (CY-
Rab5+PA). Values are expressed as a percentage of the fusion observed with control cytosol without any addition. The data are representative
of at least four independent experiments.
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both the FYVE ¢nger [26] and the C2H2 zinc binding domains
from EEA1 has not shown signi¢cant similarity (Blast 2.0.6).
Stenmark et al. [28] have shown that Rab5 in its GTP-
bound form binds rabaptin-5. This protein inhibits Rab5-
GAP activity of membranes and may regulate the GTP-
GDP cycle of Rab5 [6]. Recently, Horiuchi et al. [29] have
described a novel Rab5 GDP/GTP exchange factor and Xiao
et al. [30] have shown that the tuberous sclerosis 2 gene prod-
uct, tuberin, functions as a Rab5 GAP. Since none of these
proteins contain a zinc binding domain and presumably do
not bind phorbol esters, the phorbol ester binding factor may
be acting downstream of these proteins or may interact with
Rab5 in conjunction with them. A GDI displacement factor
that releases endosomal Rab GTPases from Rab-GDI has
also been described [31]. Nevertheless, our experiments clearly
indicate that the PMA binding protein is acting after the
Rab5 activation step, therefore, after the action of a GDI
displacement factor.
The nature of the phorbol ester binding factor is at present
unknown. The best characterized proteins that bind phorbol
esters belong to the PKC family. However, some other pro-
teins can bind phorbol esters with high a⁄nity [32]. PKC and
PKC-like molecules have been conspicuously implicated in
both the exocytotic and endocytotic pathways. PMA is be-
lieved to regulate the movement of a number of cell surface
receptors in a PKC sensitive fashion. Thus, PMA has been
demonstrated to stimulate the transcytosis and apical recy-
cling of the polymeric immunoglobulin receptor in MDCK
cells, potentially involving either the K and/or O isozymes
[33]. PMA has also been suggested to induce rapid endocyto-
sis and down modulation of the chemokine receptor CXCR4
that is required, together with CD4, for the entry of T cell line
adapted HIV-1 [34]. Moreover, two laboratories have directly
involved phorbol ester binding factors in vesicular transport
by using in vitro assays. Fabri et al. [35] have shown that the
export of the vesicular stomatitis virus glycoprotein from the
endoplasmic reticulum requires a phorbol ester binding pro-
tein. Simons et al. [36,37] have shown that the generation of
vesicles from puri¢ed Golgi fractions requires a protein kinase
C-like factor. Interestingly, both groups have reported that a
kinase activity is not necessary for the e¡ect of the factor(s).
Consistent with the results observed in the exocytotic path-
way, a kinase activity is probably not directly involved in the
e¡ect of the phorbol ester binding factor acting downstream
of Rab5, as inferred from the lack of e¡ect of several inhib-
itors of the catalytic activity of PKC. This observation does
not exclude the possibility that the phorbol ester binding fac-
tor could be a member of the PKC family because some
functions of PKC proteins are not related to the kinase activ-
ity of these enzymes. A relevant example is the synergistic
activation of phospholipase D (PLD) by PKCK and small
GTPases, such as rho and ARF, in a process independent
of the kinase activity of PKCK [38]. Phosphatidic acid, the
product of PLD activation has been implicated in a cascade
of events leading to the formation of a membrane microdo-
main enriched in acidic phospholipids that can promote mem-
brane destabilization and fusion [39].
The factor necessary for the Rab5 e¡ect on endosome fu-
sion can be related to other phorbol ester binding proteins.
Beta2-chimaerin is a high a⁄nity phorbol ester receptor and a
p21rac-GTPase activating protein [32], indicating that mem-
bers of the chimaerin family can interact with small GTPases.
Further work will be required to identify and characterize the
PMA binding protein required for the e¡ect of Rab5 in endo-
some fusion.
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